Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study

Lung Cancer. 2019 Dec:138:139-140. doi: 10.1016/j.lungcan.2019.10.027. Epub 2019 Nov 2.

Authors

W A Buikhuisen¹, F Qayyum², S G Armato 3rd², P Baas³

Affiliations

¹ The Netherlands Cancer Institute, Department of Thoracic Oncology, Amsterdam, the Netherlands. Electronic address: [email protected].
² The University of Chicago, Department of Radiology, Chicago, Illinois, USA.
³ The Netherlands Cancer Institute, Department of Thoracic Oncology, Amsterdam, the Netherlands; Leiden University Medical Center, Department of Pulmonary disease, Leiden, the Netherlands.

PMID: 31733933
DOI: 10.1016/j.lungcan.2019.10.027

No abstract available

Publication types

Letter
Validation Study

MeSH terms

Antineoplastic Agents / therapeutic use
Clinical Trials, Phase III as Topic
Disease Progression
Humans
Lung Neoplasms / diagnostic imaging*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Mesothelioma / diagnostic imaging*
Mesothelioma / drug therapy
Mesothelioma / pathology
Mesothelioma, Malignant
Pleural Neoplasms / diagnostic imaging*
Pleural Neoplasms / drug therapy
Pleural Neoplasms / pathology
Randomized Controlled Trials as Topic
Response Evaluation Criteria in Solid Tumors*
Retrospective Studies
Treatment Outcome

Substances

Antineoplastic Agents